Study title: Efficacy and safety of Symbicort® Turbuhaler® 160/4.5 ìg/inhalation, two inhalations twice daily plus as-needed, compared with Seretide™ Diskus™ 50/500 ìg/inhalation, one inhalation twice daily plus terbutaline Turbuhaler 0.4 mg/inhalation as-needed - a 6-month, randomised, double-blind, parallel-group, active-controlled, multi-national phase IIIB study in adult and adolescent patients with persistent asthma (AHEAD)
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Respiratory Tract Diseases [C08] | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: BUDESONIDE | |||||
| ATC code: | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: D5890C00002 | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | Y | Y | |